Presentation is loading. Please wait.

Presentation is loading. Please wait.

 (mostly) Psychopharmacology in Primary Care Dr. Robert Granger, MD FRCPC Thursday, September 4, 2014.

Similar presentations

Presentation on theme: " (mostly) Psychopharmacology in Primary Care Dr. Robert Granger, MD FRCPC Thursday, September 4, 2014."— Presentation transcript:

1  (mostly) Psychopharmacology in Primary Care Dr. Robert Granger, MD FRCPC Thursday, September 4, 2014

2 Outline  Common psych conditions in primary care  Psychopharmacotherapy  Non-medication therapy  Resources in Calgary  When to refer to psych

3 Ψ conditions in primary care  National Comorbidity Survey (Kessler and others 1994)  DSM-III-R criteria  Adult community sample (age 15-54)

4 Ψ conditions in primary care  NCS lifetime prevalence rates  Anxiety: 24.9%  Mood: 19.3%  MDE: 17.1%  Manic episode: 1.6%  Substance: 26.6%

5 Ψ conditions in primary care  NCS comorbidity  No disorder: 52%  One disorder: 21%  Two disorders: 13%  Three disorders: 14%

6 Ψ conditions in primary care  NCS-Replication (Kessler and others 2005)  DSM-IV criteria  Adult community sample (age 18+)

7 Ψ conditions in primary care  NCS-R lifetime prevalence rates  Anxiety: 28.8%  Mood: 20.8%  MDD: 16.6%  Bipolar I-II: 3.9%  Impulse control: 24.8%  ADHD: 8.1%  Substance: 14.6%

8 Ψ conditions in primary care  NCS-R comorbidity  Any disorder: 46.4%  Two or more disorders: 27.7%  Three or more disorders: 17.3%

9 Ψ conditions in primary care  TAKE HOME:  Anxiety, mood, and substance use disorders are common  Comorbidity is common

10 Do antidepressants work?  Psychiatric medications have similar effect sizes (ES) as general medical medications (Leucht and others 2012)  Meta-analysis of various medical and psychiatric conditions, along with recommended therapies  General medical median ES: 0.37 (95% CI: 0.37-0.53)  Psychiatric median ES: 0.41 (95% CI: 0.41-0.57)

11 Do antidepressants work?  SSRIs and SNRIs overall outperform placebo based on response rates (Melander and others 2008)  Active treatment response rate: 48%  Placebo: response rate: 32%  This applies to all severities of depression

12 Do antidepressants work?  Reduce risk of depressive relapse by 70% (Geddes and others 2003)  Results seemed similar for all classes of antidepressants  Appear to reduce risk of suicide (Isacsson 2000)  Swedish naturalistic study  Antidepressant use increased 3.5 times from 1991-1996  The suicide rate dropped 19% during this time

13 Do antidepressants work?  TAKE HOME:  Yes, antidepressants work

14 Before Rx: Ax  Interview (Lam and others 2009)  Suicidality  Bipolarity  Comorbidity  Current medication use  Features informing management (e.g., psychosis)  Screening instruments  PHQ-9 for all ages (can follow treatment course)  GDS for elderly

15 When to use antidepressants  CANMAT: Severity not explicitly stated (Lam and others 2009)  APA: For all severities, mild to severe (Gelenberg and others 2010)

16 Which antidepressant to use: CANMAT  “Best” antidepressants vs. comparators (level 1 evidence): sertraline, venlafaxine, escitalopram  1 st Line: SSRI, SNRI, mirtazapine, bupropion (and others) (Lam and others 2009)

17 Which antidepressant to use: CANMAT  Choice should be based on:  Sx  Comorbidity (e.g., bupropion poor choice for depression with anxiety)  Tolerability  Previous response  Drug-drug interactions  Patient preference  Cost (Lam and others 2009)

18 Which antidepressant to use: APA  Anything goes (no 1 st line/2 nd line/etc.)  Choice of antidepressant based on  Patient factors (e.g., FHx, medical conditions)  Pharmacokinetic factors (body to drug; e.g., CYP450)

19 Which antidepressant to use: SSRI  For depression and/or anxiety  Fluoxetine (Prozac): good evidence children and adolescents  Avoid in elderly due to long half-life  Paroxetine (Paxil): good evidence in adults  Avoid in patients taking numerous other medications (drug- drug interactions)  Consider avoiding in patients who may not tolerate discontinuation syndrome

20 Which antidepressant to use: SSRI  Sertraline (Zoloft): good evidence in adults and elderly; few drug-drug interactions and side effects  Citalopram (Celexa) and escitalopram (Cipralex): good evidence in adults in elderly; clinicians favour escitalopram due to warning about QT prolongation at higher doses of citalopram; few drug-drug interactions and side effects  Fluvoxamine (Luvox): particularly good evidence in OCD; sedating; prone to more frequent drug-drug interactions

21 Which antidepressant to use: SNRI  For depression and/or anxiety  Venlafaxine (Effexor): good evidence in adults and elderly; more noradrenergic at higher doses, which can cause increased blood pressure  Duloxetine (Cymbalta): same as above; also has indication for fibromyalgia pain and neuropathic pain

22 Which antidepressant to use: bupropion (Wellbutrin)  Primarily for depression  May aggravate anxiety  “Unfairly” blacklisted for contraindication in patients with seizures or eating disorder  “Activating”

23 Which antidepressant to use: mirtazapine (Remeron)  Primarily for depression  Has limited benefit in terms of treating anxiety  Sedative  May have more rapid onset of action than other antidepressants

24 How to use antidepressants  Start low, go slow, aim high (especially with anxiety)  Monitor every 1-2 weeks at first due to high risk of suicide, then Q2-4 weeks (Lam and others 2009)  Monitor response  Clinical Global Impression  PHQ-9 for depression  HAM-D, BDI

25 How to use antidepressants  Conduct an adequate trial: Duration and Dose  CANMAT: Wait 4-6 weeks  If more than minimal improvement, wait another 2-4 weeks “before considering additional strategies” (Lam and others 2009)

26 How to use antidepressants  APA: 4-8 weeks on “maximally tolerated dose”  If less than moderate improvement, reassess Dx, assess side effects, review complicating conditions and psychosocial factors, and adjust treatment plan  Then wait another 4-8 weeks before deciding on further adjustments (Gelenberg and others 2010)

27 When antidepressants don’t work  Assess compliance  Assess adequacy of dose and duration  Reassess Dx  Could psych Sx be due to medical disorder, substances, or another psych disorder? (e.g., sleep apnea causing Sx of depression)  Assess psychosocial factors (e.g., affordability of medication, supports)

28 When antidepressants don’t work  Not everyone will respond to first choice of antidepressant  Up to 2/3 of patients will not achieve full remission with the first antidepressant trial (STAR*D: Trivedi and others 2006)  Remission rates, STAR*D:  Level 1 (citalopram) ~30%  Level 2 (switch or augment) ~50%  After all levels (more switch and augment) ~70%


30 When antidepressants don’t work: increase or switch  Increase: if medication is tolerated and dose is modest  Switch: if response remains minimal after dose optimization  Within family (SSRI to SSRI)  Outside family (SSRI to SNRI or other)  ECT or TMS

31 When antidepressants don’t work: add-on  Add-on: if response is partial but incomplete after dose optimization  Other antidepressant (regular dose of bupropion, mirtazapine)  Atypical antipsychotic (low dose of OLZ/RIS/QUE/ARI)  Other agent  Lithium: 0.5-0.8 mEq/L (600-1200 mg daily dose)  T3: 25-50 mcg daily dose  Psychotherapy Lam and others 2009

32 When antidepressants don’t work: algorithm Lam and others 2009

33 How long to use antidepressants  Treat to remission for 6-24 months  Consider treating long-term (2 years to lifetime) if:  Patient is older  Episodes are recurrent, chronic, severe, or psychotic (Lam and others 2009)

34 Antidepressant side effects  Common: headache, GI upset, sexual dysfunction (SSRI/SNRI), sedation, weight gain  Less common: anxiety, depersonalization  Rare but serious: SIADH, UGI bleed (SSRI), serotonin syndrome (SSRI/SNRI), seizure (Lam and others 2009)

35 Antidepressants and Suicidality  Antidepressants are NOT associated with increased suicidality (thinking or behaviour) or completed suicide in young adults or older adults  Young children may experience a slight increase in suicidality, but NOT completed suicide) (Lam and others, 2009)

36 Bipolar disorder  CANMAT guidelines (Yatham and others 2013)  Acute mania  Acute bipolar depression  Maintenance

37 Bipolar d/o: Acute mania  Lithium  Valproic acid (VPA)  Atypical antipsychotics

38 Bipolar d/o: Depression  Lithium  Lamotrigine  Quetiapine  Olanzapine + SSRI  Lithium/VPA + SSRI/bupropion

39 Bipolar d/o: Maintenance  Lithium  Lamotrigine  VPA  Olanzapine  Quetiapine  Aripiprazole  Risperidone long-acting injection  Ziprasidone (with lithium or VPA)

40 Non-medication: Psychotherapy  Types  Cognitive-Behavioural Therapy (CBT): depression and anxiety  Interpersonal Therapy (IPT): depression  Dialectical Behaviour Therapy (DBT): borderline PD

41 When to use psychotherapy  CANMAT  Severity not explicitly stated  Unlikely to be useful in cases of severe depression and depression with psychotic features

42 When to use psychotherapy  CANMAT  Concurrent combination Tx with meds  Superior to either modality alone  Sequential combination Tx  I.e., addition of CBT or IPT to partial responders to medication  Crossover Tx  I.e., d/c successful medication treatment and crossover to psychotherapy  Evidence for use in acute (CBT and IPT) and maintenance (CBT) phases (Parikh and others 2009)

43 When to use psychotherapy  APA  Can be sole treatment modality in mild to moderate severity  Might be particularly useful in patients with Axis II or those who wish to avoid medications (e.g., expectant mothers)  Psychotherapy and medication can be combined in all severities of depression (Gelenberg and others 2010)

44 Non-medication: Social  Social  Primary determinants of health (e.g., Mosaic PCN)  Support groups  Lifestyle modifications

45 Resources in and outside Calgary  Access Mental Health  Regional clinics  PCN-specific resources  Canadian Mental Health Association  For rural practitioners

46 Resources: Access Mental Health  From the website: “Clinicians help people navigate the addiction and mental health system. They are familiar with both Alberta Health Services and community based programs…”  Phone: (403) 943-1500  Anyone can phone for information

47 Resources: regional clinics  Distributed throughout Calgary and Alberta  NW: Northwest Community Mental Health Centre (Foothills Professional Building)  NE: Northeast Calgary Mental Health Clinic (Sunridge)  Central: Central Community Mental Health Centre (Sheldon Chumir)  Southern Alberta: Airdrie, Banff, Canmore, Chestermere, Claresholm, Cochrane, Didsbury, High River, Nanton, Black Diamond, Okotoks

48 Resources: PCN-specific  Calgary Foothills, Calgary West Central, South Calgary, and Highland (Airdrie) PCNs: BHC model  Mosaic PCN: Chronic disease management, fitness, cardiac rehab  Calgary Rural (Okotoks): Seniors and teens programs  List of PCNs: TA/Pages/ProvincialPCNSummary.aspx

49 Resources: Canadian Mental Health Association  Phone: 403.297.1700  Main website:  Community resources (Calgary Association of Self Help)  Programs (Family Support, ILS, Leisure and Recreation)  Educational resources (Your Mental Health, Understanding Mental Illness)

50 Resources for rural practitioners  Psychiatrists in local area  Rural Mental Health clinics  Telemental Health (through Ponoka)

51 When to refer to psych  Diagnostic uncertainty or complexity (e.g., comorbidity)  Suboptimal response to two or more trials after possible contributing factors are addressed  Acuity (may require telephone consultation or referral to Emergency Department)

52 Questions 

53 References  Geddes, J., Carney, S., Davies, C., Furukawa, T., Kupfer, D., Frank, E., Goodwin, G. (2003). Relapse prevention with antidepressant drug treatment in depressive disorders: a review. The Lancet. Volume 361(9358)653-661.  Gelenberg, A., Freeman, M., Markowitz, J., Rosenbaum, J., Thase, M., Trivedi, M., Van Rhoads, R. (2010). Practice Guideline for the Treatment of Patients with Major Depressive Disorder. Third Edition. American Psychiatric Assocation.  Isacsson G. (2000). Suicide prevention—a medical breakthrough? Acta Psychiatrica Scandinavica. 102(2):113-117.  Kessler, R., McGonagle, K., Zhao, S., Nelson, C., Hughes, M., Eshleman, S., Wittchen, H., and Kendler, K. (1994). Lifetime and 12-Month Prevalence of DSM-III-R Psychiatric Disorders in the United States. Archives of General Psychiatry. Volume 51(1):8-19.  Kessler, R., Berglund P., Demler, O., Jin, R., Merikangas, K., Walters, E. (2005). Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey Replication (NCS-R). Archives of General Psychiatry. Volume 62(6):593-602.  Lam, R., Kennedy, S., Grigoriadis, S., McIntyre, R., Milev, R., Ramasubbu, R., Parikh, S., Patten, S. and Ravindran, A. (2009). Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. Journal of Affective Disorders. Volume 117 (Supplement 1):S26-S43.  Leucht, S., Hierl, S., Kissling, W., Dold, M., Davis, J. (2012). Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses. British Journal of Psychiatry. Volume 200(2):97-106.  Melander, H., Salmonson, T., Abadie, E., van Zweiten-Boot, B., (2008). A regulatory Apologia—A review of placebo-contolled studies in regulatory submissions of new-generation antidepressants. European Neuropsychopharmacology. Volume 18(9):623-627.  Parikh, S., Segal, Z., Grigoriadis, S., Ravindran, A., Kennedy, S., Lam, R., Patten, S. (2009). Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. II. Psychotherapy alone or in combination with antidepressant medication. Journal of Affective Disorders. Volume 117 (Supplement 1):S15-25.  Trivedi, M., Rush, A., Wisniewski, S., Nierenberg, A., Warden, D., Ritz, L., Norquist, G., Howland, R., Lebowitz, B., McGrath, P., Shores-Wilson, K., Biggs, M., Balasubramani, G., Fava., M. (2006). Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. American Journal of Psychiatry. Volume 163(1):28-40.  Yatham, L., Kennedy, S., Parikh, S., Schaffer, A., Beaulieu, S., Alda, M., O’Donovan, C., MacQueen, G., McIntyre, R., Sharma, V., Ravindran, A., Young, L., Milev, R., Bond, D., Frey, B., Goldstein, B., Lafer, B., Birmaher, B., Ha, K., Nolen, W., Berk, M. (2013). Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disorders. Volume 15(1):1-44.

Download ppt " (mostly) Psychopharmacology in Primary Care Dr. Robert Granger, MD FRCPC Thursday, September 4, 2014."

Similar presentations

Ads by Google